FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893437090> ?p ?o ?g. }

• W2893437090 endingPage "5952" @default.
• W2893437090 startingPage "5937" @default.
• W2893437090 abstract "A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system Yanping Lu,1 Shunping Han,1 Hongyue Zheng,1 Rui Ma,1 Yuting Ping,1 Jiafeng Zou,1 Hongxia Tang,1 Yongping Zhang,2 Xiuling Xu,1 Fanzhu Li1 1College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; 2College of Pharmaceutical Sciences, Guiyang University of Chinese Medicine, Guiyang, Guizhou, China Background: The Traditional Chinese Medicine, arsenic trioxide (ATO, As2O3) could inhibit growth and induce apoptosis in a variety of solid tumor cells, but it is severely limited in the treatment of glioma due to its poor BBB penetration and nonspecifcity distribution in vivo. Purpose: The objective of this study was encapsulating ATO in the modified PAMAM dendrimers to solve the problem that the poor antitumor effect of ATO to glioma, which provide a novel angle for the study of glioma treatment. Methods: The targeting drug carrier (RGDyC-mPEG-PAMAM) was synthesized based on Arg-Gly-Asp (RGDyC) and αvβ3 integrin targeting ligand, and conjugated to PEGylated fifth generation polyamidoamine dendrimer (mPEG-PAMAM). It was characterized by nuclear magnetic resonance, fourier transform infrared spectra, Nano-particle size-zeta potential analyzer,etc. The in vitro release characteristics were studied by dialysis bag method. MTT assay was used to investigate the cytotoxicity of carriers and the antitumor effect of ATO formulation. In vitro blood-brain barrier (BBB) and C6 cell co-culture models were established to investigate the inhibitory effect of different ATO formulation after transporting across BBB. Pharmacokinetic and antitumor efficacy studies were investigated in an orthotopic murine model of C6 glioma. Results: The prepared RGDyC-mPEG-PAMAM was characterized for spherical dendrites, comparable size (21.60±6.81 nm), and zeta potential (5.36±0.22 mV). In vitro release showed that more ATO was released from RGDyC-mPEG-PAMAM/ATO (79.5%) at pH 5.5 than that of pH 7.4, during 48 hours. The cytotoxicity of PEG-modified carriers was lower than that of the naked PAMAM on both human brain microvascular endothelial cells and C6 cells. In in vitro BBB model, modification of RGDyC heightened the cytotoxicity of ATO loaded on PAMAM, due to an increased uptake by C6 cells. The results of cell cycle and apoptosis analysis revealed that RGDyC-mPEG-PAMAM/ATO arrested the cell cycle in G2-M and exhibited threefold increase in percentage of apoptosis to that in the PEG-PAMAM/ATO group. Compared with ATO-sol group, both RGDyC-mPEG-PAMAM/ATO and mPEG-PAMAM/ATO groups prolonged the half-life time, increased area under the curve, and improved antitumor effect, significantly. While the tumor volume inhibitory of RGDyC-mPEG-PAMAM/ATO was 61.46±12.26%, it was approximately fourfold higher than the ATO-sol group, and twofold to the mPEG-PAMAM/ATO group. Conclusion: In this report, RGDyC-mPEG-PAMAM could enhance the antitumor of ATO to glioma, it provides a desirable strategy for targeted therapy of glioma. Keywords: arsenic trioxide, blood-brain barrier, RGDyC, PEG co-modified, glioma targeting delivery, PAMAM dendrimer" @default.
• W2893437090 created "2018-10-05" @default.
• W2893437090 creator A5009236640 @default.
• W2893437090 creator A5051015797 @default.
• W2893437090 creator A5056399898 @default.
• W2893437090 creator A5056564578 @default.
• W2893437090 creator A5060538212 @default.
• W2893437090 creator A5063689514 @default.
• W2893437090 creator A5070737557 @default.
• W2893437090 creator A5078983941 @default.
• W2893437090 creator A5082494894 @default.
• W2893437090 creator A5091162704 @default.
• W2893437090 date "2018-10-01" @default.
• W2893437090 modified "2023-10-11" @default.
• W2893437090 title "A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system" @default.
• W2893437090 cites W1208915593 @default.
• W2893437090 cites W1966048716 @default.
• W2893437090 cites W1966336839 @default.
• W2893437090 cites W1966440835 @default.
• W2893437090 cites W1970475276 @default.
• W2893437090 cites W1973364296 @default.
• W2893437090 cites W1981853312 @default.
• W2893437090 cites W1981989535 @default.
• W2893437090 cites W1985050468 @default.
• W2893437090 cites W1998496909 @default.
• W2893437090 cites W1998948328 @default.
• W2893437090 cites W2013538198 @default.
• W2893437090 cites W2015869298 @default.
• W2893437090 cites W2017371240 @default.
• W2893437090 cites W2037700087 @default.
• W2893437090 cites W2039821207 @default.
• W2893437090 cites W2044350044 @default.
• W2893437090 cites W2047051586 @default.
• W2893437090 cites W2050881037 @default.
• W2893437090 cites W2051908019 @default.
• W2893437090 cites W2065143355 @default.
• W2893437090 cites W2067753211 @default.
• W2893437090 cites W2070003597 @default.
• W2893437090 cites W2082511916 @default.
• W2893437090 cites W2084390278 @default.
• W2893437090 cites W2091180914 @default.
• W2893437090 cites W2096287682 @default.
• W2893437090 cites W2110027836 @default.
• W2893437090 cites W2111279921 @default.
• W2893437090 cites W2113250570 @default.
• W2893437090 cites W2118044926 @default.
• W2893437090 cites W2148977460 @default.
• W2893437090 cites W2158558808 @default.
• W2893437090 cites W2238341833 @default.
• W2893437090 cites W2255868746 @default.
• W2893437090 cites W2260620286 @default.
• W2893437090 cites W2263159835 @default.
• W2893437090 cites W2324387294 @default.
• W2893437090 cites W2336240928 @default.
• W2893437090 cites W2347178103 @default.
• W2893437090 cites W2395300225 @default.
• W2893437090 cites W2460068665 @default.
• W2893437090 cites W2471619462 @default.
• W2893437090 cites W2518792546 @default.
• W2893437090 cites W2548805584 @default.
• W2893437090 cites W2575996135 @default.
• W2893437090 cites W2727421336 @default.
• W2893437090 cites W2736295016 @default.
• W2893437090 cites W2739483576 @default.
• W2893437090 cites W2778150714 @default.
• W2893437090 cites W2796882023 @default.
• W2893437090 cites W4242403727 @default.
• W2893437090 doi "https://doi.org/10.2147/ijn.s175418" @default.
• W2893437090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6173183" @default.
• W2893437090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30323584" @default.
• W2893437090 hasPublicationYear "2018" @default.
• W2893437090 type Work @default.
• W2893437090 sameAs 2893437090 @default.
• W2893437090 citedByCount "53" @default.
• W2893437090 countsByYear W28934370902019 @default.
• W2893437090 countsByYear W28934370902020 @default.
• W2893437090 countsByYear W28934370902021 @default.
• W2893437090 countsByYear W28934370902022 @default.
• W2893437090 countsByYear W28934370902023 @default.
• W2893437090 crossrefType "journal-article" @default.
• W2893437090 hasAuthorship W2893437090A5009236640 @default.
• W2893437090 hasAuthorship W2893437090A5051015797 @default.
• W2893437090 hasAuthorship W2893437090A5056399898 @default.
• W2893437090 hasAuthorship W2893437090A5056564578 @default.
• W2893437090 hasAuthorship W2893437090A5060538212 @default.
• W2893437090 hasAuthorship W2893437090A5063689514 @default.
• W2893437090 hasAuthorship W2893437090A5070737557 @default.
• W2893437090 hasAuthorship W2893437090A5078983941 @default.
• W2893437090 hasAuthorship W2893437090A5082494894 @default.
• W2893437090 hasAuthorship W2893437090A5091162704 @default.
• W2893437090 hasBestOaLocation W28934370901 @default.
• W2893437090 hasConcept C109316439 @default.
• W2893437090 hasConcept C150903083 @default.
• W2893437090 hasConcept C155672457 @default.
• W2893437090 hasConcept C171250308 @default.
• W2893437090 hasConcept C185592680 @default.
• W2893437090 hasConcept C190283241 @default.
• W2893437090 hasConcept C192562407 @default.

• next